This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Interleukin-6 (IL-6); interleukin-8 (IL-8; CXCL8)	<p>Mouse and cell culture studies suggest dual blockade of IL-6 and IL-8 could be useful for treating triple-negative breast cancer. In a human triple-negative breast cancer cell line, small hairpin RNA-mediated knockdown of the two targets decreased anchorage-independent growth and increased apoptosis compared with knockdown of either interleukin alone. In a mouse xenograft model for triple-negative breast cancer, shRNA-mediated knockdown of both IL-6 and IL-8 inhibited tumor growth, whereas knockdown of either interleukin alone did not. Next steps could include developing and evaluating inhibitors of IL-6 and IL-8 signaling in models for triple-negative breast cancer.</p> <p>SciBX 6(23); doi:10.1038/scibx.2013.571 Published online June 13, 2013</p>	Patent and licensing status unavailable	<p>Hartman, Z.C. <i>et al. Cancer Res.</i>; published online April 30, 2013; doi:10.1158/0008-5472.CAN-12-4524-T Contact: Powel H. Brown, The University of Texas MD Anderson Cancer Center, Houston, Texas e-mail: phbrown@mdanderson.org</p>